Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06863135 monotherapy in relapsed/refractory multiple myeloma after PI, IMiD, and anti-CD38
jRCT2031210228Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of elranatamab in multiple myeloma (MM) (2 cohorts), sponsored by Pfizer. Primary endpoint: objective response rate. Started Aug 2021; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210228.